{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:44:28Z","timestamp":1787503468443,"version":"build-2736575974"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,15]],"date-time":"2019-04-15T00:00:00Z","timestamp":1555286400000},"content-version":"vor","delay-in-days":1506,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Portuguesa de Cardiologia"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.repc.2014.10.005","type":"journal-article","created":{"date-parts":[[2015,3,3]],"date-time":"2015-03-03T11:07:48Z","timestamp":1425380868000},"page":"201-208","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Galectina\u20103: indicador de progn\u00f3stico. Alvo de interven\u00e7\u00e3o terap\u00eautica?"],"prefix":"10.1016","volume":"34","author":[{"given":"Ana Rita","family":"Pereira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiz","family":"Menezes Falc\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.repc.2014.10.005_bib0140","first-page":"39","article-title":"Insufici\u00eancia card\u00edaca: internamento e ambulat\u00f3rio, Unidades Especializadas Integradas em Rede","volume":"5","author":"Ceia","year":"2007","journal-title":"Rev Factores de Risco."},{"key":"10.1016\/j.repc.2014.10.005_bib0145","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1388-9842(02)00034-X","article-title":"Prevalence of chronic heart failure in Southwestern Europe: The EPICA study","volume":"4","author":"Ceia","year":"2002","journal-title":"Eur J Heart Fail."},{"key":"10.1016\/j.repc.2014.10.005_bib0150","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jacc.2006.03.061","article-title":"Utility of amino\u2010terminal pro\u2010brain natriuretic peptide, Galectin\u20103, and apelin for the evaluation of patients with acute heart failure","volume":"48","author":"Van Kimmenade","year":"2006","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.repc.2014.10.005_bib0155","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1093\/eurheartj\/ehs077","article-title":"Galectin\u20103 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA)","volume":"33","author":"Gullestad","year":"2012","journal-title":"Eur Heart J."},{"issue":"suppl 1","key":"10.1016\/j.repc.2014.10.005_bib0160","first-page":"429","article-title":"Galectin\u20103 and PIIINP are associated with cardiovascular outcomes in patients with heart failure, left ventricular dysfunction and dysynchrony. Insights from the CARE\u2010HF study","volume":"31","author":"Rossignol","year":"2010","journal-title":"Eur Heart J."},{"key":"10.1016\/j.repc.2014.10.005_bib0165","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1093\/eurjhf\/hfq091","article-title":"Galectin\u20103, cardiac structure and function, and long\u2010term mortality in patients with acutely decompensated heart failure","volume":"12","author":"Shah","year":"2010","journal-title":"Eur J Heart Fail."},{"issue":"suppl","key":"10.1016\/j.repc.2014.10.005_bib0170","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1016\/j.cardfail.2011.06.311","article-title":"Plasma Galectin\u20103 Is associated with near\u2010term rehospitalization in heart failure: A meta\u2010analysis","volume":"17","author":"De Boer","year":"2011","journal-title":"J Card Fail."},{"key":"10.1016\/j.repc.2014.10.005_bib0175","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1017\/S1462399408000719","article-title":"Galectins: Structure, function and therapeutic potential","volume":"13","author":"Yang","year":"2008","journal-title":"Expert Rev Mol Med."},{"key":"10.1016\/j.repc.2014.10.005_bib0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11897-010-0004-x","article-title":"Galectin\u20103 in cardiac remodeling and heart failure","volume":"7","author":"De Boer","year":"2010","journal-title":"Curr Heart Fail Rep."},{"key":"10.1016\/j.repc.2014.10.005_bib0185","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00392-010-0125-y","article-title":"Prognostic value of galectin\u20103, a novel marker of fibrosis, in patients with chronic heart failure: Data from the DEAL\u2010HF study","volume":"99","author":"Lok","year":"2010","journal-title":"Clin Res Cardiol."},{"key":"10.1016\/j.repc.2014.10.005_bib0190","doi-asserted-by":"crossref","first-page":"e004374","DOI":"10.1161\/JAHA.112.004374","article-title":"Galectin\u20103 in heart failure: More answers or more questions?","volume":"1","author":"Ahmad","year":"2012","journal-title":"J Am Heart Assoc."},{"key":"10.1016\/j.repc.2014.10.005_bib0195","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/eurjhf\/hfp097","article-title":"Galectin\u20103: A novel mediator of heart failure development and progression","volume":"11","author":"De Boer","year":"2009","journal-title":"Eur J Heart Fail."},{"key":"10.1016\/j.repc.2014.10.005_bib0200","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1023\/B:GLYC.0000014088.21242.e0","article-title":"Galectins as inflammatory mediators","volume":"19","author":"Almkvist","year":"2004","journal-title":"Glycoconj J."},{"key":"10.1016\/j.repc.2014.10.005_bib0205","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1161\/CIRCHEARTFAILURE.111.963637","article-title":"Galectin\u20103 in ambulatory patients with heart failure: Results from the HF\u2010ACTION study","volume":"5","author":"Felker","year":"2012","journal-title":"Circ Heart Fail."},{"key":"10.1016\/j.repc.2014.10.005_bib0210","doi-asserted-by":"crossref","first-page":"33","DOI":"10.15420\/ecr.2010.6.2.33","article-title":"Galectin\u20103 in heart failure \u2013 linking fibrosis, remodelling and progression","volume":"6","author":"DeFilippi","year":"2010","journal-title":"European Cardiology"},{"key":"10.1016\/j.repc.2014.10.005_bib0215","article-title":"2013 ACCF\/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation."},{"key":"10.1016\/j.repc.2014.10.005_bib0220","first-page":"S29","article-title":"An international consensus statement regarding amino\u2010terminal Pro\u2010B\u2010type natriuretic peptide testing: The international NT\u2010proBNP consensus panel","volume":"101","author":"Januzzi Jr","year":"2008","journal-title":"Am J Cardiol."},{"key":"10.1016\/j.repc.2014.10.005_bib0225","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3109\/07853890.2010.538080","article-title":"Predictive value of plasma galectin\u20103 levels in heart failure with reduced and preserved ejection fraction","volume":"43","author":"De Boer","year":"2011","journal-title":"Ann Med."},{"key":"10.1016\/j.repc.2014.10.005_bib0230","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-2796.2011.02476.x","article-title":"The fibrosis marker galectin\u20103 and outcome in the general population","volume":"272","author":"De Boer","year":"2012","journal-title":"J Intern Med."},{"key":"10.1016\/j.repc.2014.10.005_bib0235","doi-asserted-by":"crossref","first-page":"A26","DOI":"10.1016\/S0735-1097(10)60244-6","article-title":"Clinical and prognostic value of Galectin\u20103, a novel fibrosis\u2010associated biomarker. Relation with clinical and biochemical correlates of heart failure","volume":"55","author":"De Boer","year":"2010","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.repc.2014.10.005_bib0240","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.cardfail.2009.10.013","article-title":"Clinical and prognostic value of Galectin\u20103, a novel fibrosis\u2010associated biomarker, in patients with chronic heart failure","volume":"15","author":"Van Veldhuisen","year":"2009","journal-title":"J Card Fail."},{"key":"10.1016\/j.repc.2014.10.005_bib0245","unstructured":"About Galectin\u20103. BG Medicine, Inc. [serie na internet.] [citado 15 Jul 2013]. Dispon\u00edvel em: http:\/\/www.bg\u2010medicine.com\/galectin\u20103\/."},{"key":"10.1016\/j.repc.2014.10.005_bib0250","article-title":"Galectin\u20103 as a diagnostic and prognostic tool in heart failure","year":"2011","journal-title":"Am Coll Cardiol [serie na internet]"},{"key":"10.1016\/j.repc.2014.10.005_bib0255","first-page":"A10012","article-title":"Galectin\u20103 is a strong early predictor of mortality in severe congestive heart failure","volume":"124","author":"Rousseau","year":"2011","journal-title":"Circulation."},{"key":"10.1016\/j.repc.2014.10.005_bib0260","doi-asserted-by":"crossref","first-page":"H404","DOI":"10.1152\/ajpheart.00747.2008","article-title":"N\u2010acetyl\u2010seryl\u2010aspartyl\u2010lysyl\u2010proline prevents cardiac remodeling and dysfunction induced by galectin\u20103, a mammalian adhesion\/growth\u2010regulatory lectin","volume":"296","author":"Liu","year":"2009","journal-title":"Am J Physiol Heart Circ Physiol."},{"key":"10.1016\/j.repc.2014.10.005_bib0265","first-page":"1097","article-title":"Pharmacological inhibition of Galectin\u20103 attenuates adverse cardiac remodeling and heart failure","volume":"32","author":"Yu","year":"2011","journal-title":"Eur Heart J."},{"key":"10.1016\/j.repc.2014.10.005_bib0270","first-page":"1094","article-title":"Genetic disruption of Galectin\u20103 prevents adverse cardiac remodeling","volume":"32","author":"Yu","year":"2011","journal-title":"Eur Heart J."}],"container-title":["Revista Portuguesa de Cardiologia"],"original-title":[],"language":"pt","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0870255115000359?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0870255115000359?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:02:22Z","timestamp":1760108542000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0870255115000359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S0870255115000359"],"URL":"https:\/\/doi.org\/10.1016\/j.repc.2014.10.005","relation":{},"ISSN":["0870-2551"],"issn-type":[{"value":"0870-2551","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Galectina\u20103: indicador de progn\u00f3stico. Alvo de interven\u00e7\u00e3o terap\u00eautica?","name":"articletitle","label":"Article Title"},{"value":"Revista Portuguesa de Cardiologia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.repc.2014.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Sociedade Portuguesa de Cardiologia. Published by Elsevier Espa\u00f1a, S.L. All rights reserved.","name":"copyright","label":"Copyright"}]}}